RESUMO
No disponible
Assuntos
Humanos , Feminino , Adulto , Linfoma , Neoplasias Primárias Múltiplas/complicações , Neoplasias Primárias Múltiplas , Fluordesoxiglucose F18/administração & dosagem , Fluordesoxiglucose F18/análise , Tomografia por Emissão de Pósitrons , Neoplasias Ósseas , Hiperemia , Antígenos CD20/administração & dosagem , Antígenos CD20/análise , Antígenos CD79/administração & dosagem , Antígenos CD79/análise , Coloide de Enxofre Marcado com Tecnécio Tc 99m/análiseRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Medicina Nuclear/história , Medicina Nuclear/métodos , Medicina Nuclear/tendências , Congressos como Assunto/tendências , Medicina Nuclear/organização & administração , Medicina Nuclear/normasAssuntos
Humanos , Feminino , Pessoa de Meia-Idade , Tecnécio Tc 99m Exametazima , Doenças da Glândula Tireoide , Testes de Função Tireóidea , Glândula Tireoide/patologia , Glândula Tireoide , Hipercolesterolemia/complicações , Hipercolesterolemia/diagnóstico , /métodos , Glândula Tireoide , Diagnóstico DiferencialRESUMO
Llevamos a cabo un estudio retrospectivo para evaluar la exactitud, validez diagnóstica e impacto clínico de la 18F-FDG PET en el manejo de enfermedad metastásica y recurrente en pacientes con carcinoma de células renales (CCR) de nuestra base de datos. Se identificaron estudios 18F-FDG PET de 58 pacientes que cumplían con nuestros criterios de inclusión en el estudio. Se confirmaron los resultados con los hallazgos histopatológicos, seguimiento clínico (al menos 12 meses) y/o métodos convencionales de imagen (MCI).Se obtuvo una sensibilidad de 80,56%, especificidad 86,36%, exactitud dignóstica 58,7%, valor predictivo positivo 90,63%, y valor predictivo negativo 73.08%.El impacto clínico fue elevado en 25 casos (43%) y no hubo impacto en sólo 10 estudios (17,2%). Concluimos que la 18F-FDG PET es útil y que tiene elevado impacto clínico en el manejo de CCR metastático y recurrente. Basado en nuestros resultados, un estudio PET positivo fue de más ayuda al clínico que un estudio negativo en el manejo de estos pacientes(AU)
We performed a retrospective study to evaluate the accuracy, diagnostic validity, and clinical impact of 18F-FDG PET in the management of recurrent and metastatic disease in patients with Renal Cell Carcinoma (RCC) from our database. 18F-FDG PET studies were identified from 58 patients that matched our criteria for inclusion in the study. Results were confirmed with histopathological findings, clinical follow-up time (at least 12 months), and/ or conventional imaging methods (CIM).A sensitivity of 80.56%, specificity 86.36%, diagnostic accuracy 58.7%, positive predictive value 90.63%, and a negative predictive value of 73.08% were observed.The clinical impact was high in 25 cases (43%) and we found no impact in only 10 studies (17.2%). We concluded that 18F-FDG PET was useful and had a high clinical impact in the management of recurrent and metastatic RCC. From our data, it seemed that a positive PET study was more helpful to the physician than a negative study(AU)
Assuntos
Humanos , Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons/instrumentação , Tomografia por Emissão de Pósitrons/métodos , Carcinoma de Células Renais/diagnóstico , Sensibilidade e Especificidade , Valor Preditivo dos Testes , Carcinoma de Células Renais , Estudos RetrospectivosRESUMO
We performed a retrospective study to evaluate the accuracy, diagnostic validity, and clinical impact of (18)F-FDG PET in the management of recurrent and metastatic disease in patients with Renal Cell Carcinoma (RCC) from our database. (18)F-FDG PET studies were identified from 58 patients that matched our criteria for inclusion in the study. Results were confirmed with histopathological findings, clinical follow-up time (at least 12 months), and/ or conventional imaging methods (CIM). A sensitivity of 80.56%, specificity 86.36%, diagnostic accuracy 58.7%, positive predictive value 90.63%, and a negative predictive value of 73.08% were observed. The clinical impact was high in 25 cases (43%) and we found no impact in only 10 studies (17.2%). We concluded that (18)F-FDG PET was useful and had a high clinical impact in the management of recurrent and metastatic RCC. From our data, it seemed that a positive PET study was more helpful to the physician than a negative study.
